Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Counseling and testing intravenous-drug users for HIV infection - Boston

Article Abstract:

To increase the rate of counseling and human immunodeficiency virus (HIV) infection testing of intravenous-drug users, Project TRUST (Teaching, Referral, Understanding, Support and Testing) has been established by a consortium of medical institutions in the Boston area. Despite the known increased risk for AIDS (acquired immunodeficiency syndrome) among intravenous-drug users, few have been tested for the HIV, or have received counseling. There are an estimated 14,000 intravenous-drug users in the metropolitan Boston area, and yet only 473 of them identified themselves for anonymous counseling and testing in 1988. TRUST staff includes nurses, counselors and outreach workers, who provide these services without charge and are located within high risk neighborhoods. During its first year of operation, 688 clients were seen, of whom 107 (17 percent) tested positive for the AIDS virus. Of those tested 79 percent returned to receive the results and to obtain counseling. The provision of personnel and facilities cost approximately $253 per client served.

Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1989
Health aspects, Economic aspects, Services, Boston, Massachusetts, AIDS patients, Medical screening, Health screening, HIV testing, HIV tests, Diagnostic services, column, Boston

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache

Article Abstract:

To test the effectiveness of the intravenous administration of the drug prochlorperazine in the treatment of acute headaches, patients with severe vascular or tension headaches were injected either with the drug or with a solution of no pharmacological value (a placebo). Within an hour, 88 percent of the patients who had received the drug experienced complete or partial pain relief. Only 45 percent of the placebo group had pain relief. Very few side effects were noted from use of the drug. Intravenous prochlorperazine is considered to be a safe and effective treatment of severe headaches.

Author: Jones, Jeffrey, Sklar, David, Dougherty, James, White, William
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1989
Testing, Prochlorperazine

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Headache assessment and management

Article Abstract:

The diagnosis and treatment of headaches and migraines are reviewed. Most people will have a headache at one time or another throughout their lives, and pain-killers for headache are one of the most commonly prescribed drugs.

Author: Kaniecki, Robert
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2003
Diagnosis, Migraine

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Drug therapy, Headache
Similar abstracts:
  • Abstracts: Quality indicators for patient information in short-stay units
  • Abstracts: Child molestation and pedophilia: an overview for the physician. The controversy over radiation safety: a historical overview
  • Abstracts: Do bacteria cause chronic polyarthritis? A defective beta-cell glucose sensor as a cause of diabetes. SIDS - a syndrome in search of a cause
  • Abstracts: Treatment of alcoholism. Medical disorders of alcoholism. The pharmacological treatment of depression
  • Abstracts: Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. part 2 Viral entry denied
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.